Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: Clinical and biologic activities in the phase 1 setting

Blood

Volumn 102, Issue 13, 2003, Pages 4527-4534

  Kurzrock, Razelle ^a   Kantarjian, Hagop M ^b   Cortes, Jorge E ^b   Singhania, Neil ^b   Thomas, Deborah A ^b   Wilson, Edward F ^b   Wright, John J ^b   Freireich, Emil J ^b   Talpaz, Moshe ^b   Sebti, Saïd M ^b  

^a Unit 422   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GERANYLGERANYLTRANSFERASE 1; INTERLEUKIN 10; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE B; STAT3 PROTEIN; TIPIFARNIB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; BONE PAIN; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FATIGUE; FEMALE; GENE MUTATION; HEADACHE; HUMAN; HUMAN CELL; MALE; MAXIMUM TOLERATED DOSE; MYALGIA; MYELODYSPLASTIC SYNDROME; NAUSEA; ONCOGENE K RAS; ONCOGENE N RAS; PHASE 1 CLINICAL TRIAL; PRENYLATION; PRIORITY JOURNAL; RASH; REFRACTORY ANEMIA; REMISSION; THROMBOCYTE COUNT; VISUAL DISORDER;

EID: 10744227474     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-11-3359     Document Type: Article

References (57)

1. Reuter CW, Morgan MA, Bergmann L. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood. 2000;96:1655-1669.
2. Beaupre DM, Kurzrock R. RAS and leukemia: from basic mechanisms to gene-directed therapy. J Clin Oncol. 1999;17:1071-1079.
3. End DW, Smets G, Todd AV, et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 2001;61:131-137.
4. Karp JE, Kaufmann SH, Adjei AA, Lancet JE, Wright JJ, End DW. Current status of clinical trials of farnesyltransferase inhibitors. Curr Opin Oncol. 2001;13:470-476.
5. Ashar HR, James L, Gray K, et al. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem. 2000;275:30451-30457.
6. Sebti SM, Hamilton AD. Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bed-side issues. Exp Opin Invest Drugs. 2000;9:2767-2782.
7. Crespo NC, Ohkanda J, Yen TJ, Hamilton AD, Sebti SM. The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells. J Biol Chem. 2001;276:16161-16167.
8. Quinn MT. Low-molecular weight GTP-binding proteins and leukocyte signal transduction. J Leuk Biol. 1995;58:263-276.
9. Bokoch GM, Der CJ. Emerging concepts in the RAS superfamily of GTP-binding proteins. FASEB J. 1991;7:750-759.
10. Boguski MS, McCormick F. Proteins regulating RAS and its relatives. Nature. 1993;366:643-653.
11. Shimizu K, Goldfarb M, Suard Y, et al. Three human transforming genes are related to the viral oncogenes. Proc Natl Acad Sci U S A. 1983;80:2112-2116.
12. Rodenhuis S. Ras and human tumors. Semin Cancer Biol. 1992;3:241-247.
13. Parker J, Mufti GJ. Ras and myelodysplasia: lessons from the last decade. Semin Hematol. 1996;33:206-224.
14. Hirsch-Ginsberg C, Lemaistre AC, Kantarjian H, et al. Ras muations are rare events in Philadelphia chromosome negative/bcr gene rearrangement-negative chronic myelogenous leukemia but are prevalent in chronic myelomonocytic leukemia. Blood. 1990;76:1214-1219.
15. Nounou R, Estey E, Beran M, et al. Mutation of K-, N-, and H-RAS oncogenes in patients with MDS [abstract]. Blood. 1996;88(suppl 1):208b.
16. Imamura N, Kuramoto A, Ishihara H, et al. Detection of high incidence of H-RAS oncogene point mutations in acute myelogenous leukemia. Am J Hematol. 1993;43:151-153.
17. Neri A, Knowles DM, Greco A, et al. Analysis of RAS oncogene mutations in human lymphoid malignancies. Proc Natl Acad Sci U S A. 1988;85:9268-9272.
18. Liu P, Leong T, Quam L, et al. Activating mutations of N- and K-RAS in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood. 1996;88:2699-2706.
19. Willumsen BM, Noriss K, Papgeorge AG, et al. Harvey murine sarcoma virus p21 RAS protein: biological and biochemical significance of the cysteine nearest the carboxy terminus. EMBO J. 1984;3:2581-2585.
20. Jackson JH, Cochrane CG, Bourne JR, et al. Farnesyl modification of Kirstein-RAS exon 4B protein is essential for transformation. Proc Natl Acad Sci U S A. 1990;87:3042-3046.
21. Sun J, Qian Y, Hamilton AD, Sebti SM. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-RAS prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Oncogene. 1998;16:1467-1473.
22. Lerner, EC, Zhang TT, Knowles D, Qian Y, Hamilton AD, Sebti SM. Inhibition of the prenylation of K-RAS, but not H- or N-RAS is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines. Oncogene. 1997;15:1283-1288.
23. Sun Z, Qian Y, Hamilton AD, Sebti SM. Ras CAAX peptidomimetic FTI-276 selectively blocks in nude mice the growth of a human lung carcinoma with a K-RAS mutation and a p53 deletion. Cancer Res. 1995;55:4243-4247.
24. End D, Skrzat S, Devine A, et al. R115777, a novel imidazole farnesyl protein transferase inhibitor (FTI): biochemical and cellular effects of H-RAS and K-RAS dominant systems [abstract]. Proc Am Assoc Cancer Res. 1998;39:270.
25. Skrzat S, Angibaud P, Venet M, Sanz G, Bowden C, End D. R115777, a novel imidazole farnesyl protein transferase inhibitor (FTI) with potent oral antitumor activity [abstract]. Proc Am Assoc Cancer Res. 1998;39:317.
26. Smets G, Xhonneux B, Cornelissen F, End D, Bowden C, Wouters W. R115777, a selective farnesyl protein transferase inhibitor (FTI), induces anti-angiogenic, apoptotic and anti-proliferative activity in CAPAN-2 and in LoVo tumor xenografts [abstract]. Proc Am Assoc Cancer Res. 1996;39:318.
27. Venet M, Angibaud P, Sanz G, Poignet H, End D, Bowden C. Synthesis and in vitro structure-activity relationships of imidazolyl-2-quinolinones as farnesyl protein transferase inhibitors (FTI) [abstract]. Proc Am Assoc Cancer Res. 1998;39:318.
28. Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood. 2001;97:3361-3369.
29. Beaupre DM, Talpaz M, Marini FC 3rd, et al. Autocrine interleukin-1β production in leukemia: evidence for the involvement of mutated RAS. Cancer Res. 1999;59:2971-2980.
30. Nigam M, Seong CM, Qian Y, Hamilton AD, Sebti SM. Potent inhibition of human tumor p21 RAS farnesyltransferase by A1A2-lacking CA1A2X peptidomimetics. J Biol Chem. 1993;268:2069-520698.
31. Harris N, Jaffe E, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting. J Clin Oncol. 1999;17:3835-3849.
32. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndrome. Br J Haematol. 1982;51:189-199.
33. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndrome. Blood. 1997;89:2079-2088.
34. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96:3671-3674.
35. Jiang K, Coppola D, Crespo NC, et al. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol Cell Biol. 2000;20:139-148.
36. Gibbs JB, Oliff A. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Ann Rev Pharmacol Toxicol. 1997;37:143-166.
37. James GL, Brown MS, Cobb MH, et al. Benzodiazepine peptidomimetic BZA-5B interrupts the MAP kinase activation pathway in H-RAS-transformed Rat-1 cells, but not in untransformed cells. J Biol Chem. 1994;269:27705-27714.
38. Kohl NE, Wilson FR, Mosser SD, et al. Protein farnesyltransferase inhibitors block the growth of RAS-dependent tumors in nude mice. Proc Natl Acad Sci U S A. 1994;91:9141-9145.
39. Hagasu T, Yoshimatsu K, Rowell C, Lewis MD, Garcia AM. Inhibition of human tumor xenograft growth by treatment with farnesyl transferase inhibitor B9576. Cancer Res. 1995;55:5310-5314.
40. Kohl NE, Omer CA, Conner MW, et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in RAS transgenic mice. Nat Med. 1995;1:792-797.
41. Mangues R, Corral T, Kohl NE, et al. Antitumor effects of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-RAS in transgenic mice. Cancer Res. 1998;58:1253-1259.
42. Kohl, NE, Mosser SD, DeSolms SJ, et al. Selective inhibition of RAS-dependent transformation by a farnesyltransferase inhibitor. Science. 1993;260:1934-1937.
43. Kaufman R, Qian Y, Bogt A, Sebti SM, Hamilton AD, Carthew R. Activated Drosophila Ras 1 is selectively suppressed by isoprenyltransferase inhibitors. Proc Natl Acad Sci U S A. 1995;92:10919-10923.
44. Schwartz G, Rowinsky EK, Rha SY, et al. A phase I, pharmacokinetic, and biologic correlative study of R115777 and Trastuzumab (Herceptin) in patients with advanced cancer [abstract]. Proc Am Soc Clin Oncol. 2001;20:81a.
45. Adjei AA, Erlichman C, Marks RS, et al. A phase I trial of the farnesyltransferase inhibitor R115777, in combination with gemcitabine and cisplatin in patients with advanced cancer [abstract]. Proc Am Soc Clin Oncol. 2001;20:81a.
46. Verweij J, Kehrer DFS, Planting AS, et al. A phase I trial of irinotecan in combination with the farnesyl transferase inhibitor (FTI) R115777 [abstract]. Proc Am Soc Clin Oncol. 2001;20:81a.
47. Piccart-Gebhart MJ, Branle F, de Valeriola D, et al. A phase I, clinical and pharmacokinetic (PK) trial of the farnesyl transferase inhibitor (FTI) R115777 + docetaxel: a promising combination in patients (PTS) with solid tumors [abstract]. Proc Am Soc Clin Oncol. 2001;20:80a.
48. Nakagawa K, Yamamoto N, Nishio K, et al. A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of the farnesyl transferase inhibitor (FTI) R115777 in Japanese patients with advanced non-hematological malignancies [abstract]. Proc Am Soc Clin Oncol. 2001;20:80a.
49. Voi M, Tabernero J, Cooper MR, et al. A phase I study of the farnesyltransferase (FT) inhibitor BMS-214662 administered as a weekly 1-hour infusion in patients (Pts) with advanced solid tumors: clinical findings [abstract]. Proc Am Soc Clin Oncol. 2001;20:79a.
50. Camacho LH, Soignet SL, Pezzulli S, et al. Dose escalation study of oral farnesyl transferase inhibitor (FTI) BMS-214662 in patients with solid tumors [abstract]. Proc Am Soc Clin Oncol. 2001;20:79a.
51. Heaney ML, Golde DW. Myelodysplasia. N Engl J Med. 1999;349:1649-1660.
52. Taylor KM, Rodwell RL, Taylor DL, Seeley GO. Myelodysplasia. Curr Opin Oncol. 1994;6:32-40.
53. Bollag G, Clapp DW, Shih S, et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in hematopoietic cells. Nat Genet. 1996;12:144-148.
54. Lee YY, Kim WS, Bang YJ, et al. Analysis of mutations of neurofibromatosis type I gene and N-RAS gene in acute myelogenous leukemia. Stem Cells. 1995;13:556-563.
55. Albitor M, Estey E, Doherty D, et al. Prognostic significance of cytokine levels in newly diagnosed AML and high-risk myelodysplasia [abstract]. Blood. 2001;98:327a.
56. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20:2429-2440.
57. Johnston SRD. Farnesyl transferase inhibitors: a novel targeted therapy for cancer. Lancet Oncol. 2001;2:18-26.